Fan, Xiaoxu
Mocchi, Madaline
Pascuzzi, Bailey
Xiao, Jiayang
Metzger, Brian A.
Mathura, Raissa K.
Hacker, Carl
Adkinson, Joshua A.
Bartoli, Eleonora
Elhassa, Salma
Watrous, Andrew J.
Zhang, Yue http://orcid.org/0000-0002-2868-9941
Allawala, Anusha
Pirtle, Victoria
Mathew, Sanjay J. http://orcid.org/0000-0002-2715-6641
Goodman, Wayne
Pouratian, Nader http://orcid.org/0000-0002-0426-3241
Bijanki, Kelly R. http://orcid.org/0000-0003-1624-8767
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
Article History
Received: 30 August 2023
Accepted: 15 March 2024
First Online: 16 April 2024
Competing interests
: W.G. receives royalties from Nview, LLC and OCDScales, LLC. N.P. is a consultant for Abbott Laboratories and Sensoria Therapeutics. S.J.M has received consultant fees from Abbott, Almatica Pharma, Beckley Psytech, Biohaven, BioXcel Therapeutics, Boehringer-Ingelheim, Brii Biosciences, Clexio Biosciences, COMPASS Pathways, Delix Therapeutics, Douglas Pharmaceuticals, Engrail Therapeutics, Freedom Biosciences, LivaNova, Levo Therapeutics, Merck, Motif Neurotech, Neumora, Neurocrine, Perception Neuroscience, Praxis Precision Medicines, Relmada Therapeutics, Sage Therapeutics, Seelos Therapeutics, Signant Health, Sunovion Pharmaceuticals, Xenon Pharmaceuticals, Worldwide Clinical Trials and XWPharma. S.J.M has received research support from Boehringer-Ingelheim, Engrail Therapeutics, Merck, Neurocrine and Sage Therapeutics. The other authors declare no competing interests.